Identificador persistente para citar o vincular este elemento:
https://accedacris.ulpgc.es/jspui/handle/10553/158860
| Título: | Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience | Autores/as: | Kirchgesner, Julien Beaugerie, Laurent Baumann, Cédric Baert, Filip Rahier, Jean‐François Bergemalm, Daniel Cañete, Fiorella Caron, Bénédicte Cossignani, Marta Dias, Sandra Farkas, Klaudia Girod, Parker Goren, Idan Holvoet, Tom Krasz, Susanne Kumar, Aditi Rimmer, Peter Sheridan, Juliette Thut, Jessica Uzzan, Mathieu Viazis, Nikos Weimers, Petra Zagórowicz, Edyta Buisson, Anne Avedano, Luisa Rousseau, Helene Peyrin‐Biroulet, Laurent Sebastian, Shaji Ceballos Santos, Daniel Sebastián |
Clasificación UNESCO: | 32 Ciencias médicas 3201 Ciencias clínicas 320503 Gastroenterología |
Fecha de publicación: | 2026 | Publicación seriada: | Clinical pharmacology and therapeutics | Resumen: | Investigator-initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I-CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years. We describe patients and investigators' involvement in I-CARE and identify predictors of early withdrawal due to patient non-engagement. Patients' characteristics according to the number of electronic Patient-reported outcomes (ePRO) completed during follow-up were assessed. Predictors of early withdrawal due to patient non-engagement were identified using logistic regression. The coding of outcomes reported by patients and corrections by investigators on patients' ePROs were assessed. Among 12,846 patients included by 502 investigators, 79.3% and 77.3% filled more than one ePRO and at least one ePRO within 6 months before the study end date, respectively. All ePROs were completed in 72.8% and 56.4% of patients during year 1 and 3, respectively. Male gender, younger age (< 20), being unemployed or a student, and no previous history of abdominal surgery were associated with early withdrawal. Investigators corrected 52.5% of cancer or dysplasia reported by patients compared to 10% of serious infections. Investigators added or removed a treatment sequence in 19.6% of the 6708 patients treated with biologics. These results highlight the implication of patients in research and the importance of data validation by investigators alongside the challenge and potential of collecting medical data from patients. These findings can inform similar future initiatives in other diseases. | URI: | https://accedacris.ulpgc.es/jspui/handle/10553/158860 | ISSN: | 0009-9236 | DOI: | 10.1002/cpt.70231 | Fuente: | Clinical pharmacology and therapeutics, [ISSN 0009-9236], 2026 |
| Colección: | Artículo de prensa |
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.